DecisionView's Linda Drumright to Chair Panel on Patient Enrollment at the 46th DIA Annual Meeting on June 15, 2010

Wednesday, June 9, 2010 General News J E 4
SAN FRANCISCO, June 8 DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, is pleased to announce that DecisionView President and COO Linda Drumright will moderate an expert panel discussion on Patient Enrollment at the 46th DIA Annual Meeting (June 13-17, 2010 in Washington, D.C.). Ms. Drumright will be joined by industry experts from Pfizer and GlaxoSmithKline, who will share their first-hand experiences in driving the evolution of patient enrollment processes within their organizations.

Patient Enrollment is at the heart of all clinical trials. Yet in many organizations, the systems and tools available for planning and tracking trials are immature, require manual inputs, and lack the features and flexibility clinical planners and trial managers need. The result: 72% of studies are delayed by more than a month, at an average cost of $37,000 per day.

Industry experts from Pfizer, GlaxoSmithKline and DecisionView will share their first-hand experiences in evolving patient enrollment processes to foster collaboration and data-driven decision-making through an enrollment "planning culture." During the session, panelists will address some of the most challenging enrollment performance issues faced by the industry today, including:

In addition, the session will include expert presentations by each of the panelists, including:


DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by four of the top ten global pharmaceutical companies, and has been used on over 750 clinical studies with over 120,000 subjects enrolled in over ten different therapeutic areas. Primary investors in the company include Granite Ventures, Adobe Ventures, and Aeris Capital. For additional information about DecisionView, go to or call 415-538-1800.


The DIA Annual Meeting is the premier event for professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, medical devices, and related products. DIA is a neutral, global, professional, member-driven association of nearly 18,000 industry, academia, and regulatory professionals involved in the discovery, development, and life cycle management of pharmaceuticals, medical devices, and related products. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

-- Standardizing the enrollment planning process -- Visibility of enrollment performance across the portfolio -- Planning's impact on downstream trial execution -- Reducing enrollment forecast variability and risks -- Use of historical enrollment data in planning -- Global collaboration

SOURCE DecisionView Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Flag View Cougar Pride Students Thank Nevada State...
Vermont Selects JEN Associates to Provide Medicare...